In response to a study that found risk of Guillain-Barré syndrome increased slightly after receiving the recombinant zoster vaccine (RZV; Shingrix), Dennis Bourdette, M.D., says: "The recombinant zoster vaccine dramatically reduces the risk of developing shingles. Patients should be cautioned about the small risk of GBS following vaccination but also told about the serious problems associated with developing shingles, which are preventable by the recombinant zoster vaccine."

Muriel Lezak, M.D., emeritus professor of neurology, neurosurgery and psychiatry and author of a landmark textbook on brain injuries and disorders, passed away Oct. 6.

A study led by OHSU's Lars Grosse-Wortmann, M.D., finds cooperation during pediatric MRIs improves with parental participation.

Portland-based Oregon Health & Science University's board of directors approved a $650 million expansion to its hospital Oct. 29, which was delayed by the COVID-19 pandemic.

The board of directors at Oregon Health & Science University on Friday approved the new $650 million proposal to expand the hospital in Southwest Portland.

Under state rules, employees seeking a religious exception have only to attest to “sincerely held religious beliefs” against vaccination or provide a doctor’s note with a medical reason for forgoing inoculation.

OHSU denied more than 93% of exception applications, approving just 30 of 424 religious or medical requests processed so far.

The Portland Business Journal reports on Lawrence Furnstahl's budget presentation at the Oct. 29 board of directors meeting.

Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world’s second leading cause of blindness.

Oregon Health and Science University (OHSU) is facing a fresh round of capacity issues and is having to divert patients to other hospitals and reschedule surgeries, according to a message from the hospital's executive leadership team sent to staff on Thursday.